Celldex Therapeutics (NASDAQ:CLDX) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research report report published on Thursday morning,Benzinga reports. The firm currently has a $67.00 target price on the biopharmaceutical company’s stock.

Other research analysts also recently issued reports about the company. Wolfe Research downgraded Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Citigroup started coverage on shares of Celldex Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $70.00 price target for the company. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Finally, The Goldman Sachs Group initiated coverage on shares of Celldex Therapeutics in a research note on Monday, September 30th. They set a “neutral” rating and a $45.00 target price for the company. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Stock Up 2.1 %

Shares of CLDX opened at $25.79 on Thursday. The company has a market capitalization of $1.71 billion, a P/E ratio of -10.04 and a beta of 1.57. Celldex Therapeutics has a twelve month low of $22.93 and a twelve month high of $53.18. The firm has a 50 day moving average of $26.12 and a 200 day moving average of $32.76.

Insider Transactions at Celldex Therapeutics

In related news, CEO Anthony S. Marucci acquired 11,500 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was bought at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the purchase, the chief executive officer now owns 40,284 shares in the company, valued at $1,080,416.88. The trade was a 39.95 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Celldex Therapeutics

Several large investors have recently added to or reduced their stakes in CLDX. Bank of New York Mellon Corp raised its holdings in Celldex Therapeutics by 14.6% during the second quarter. Bank of New York Mellon Corp now owns 230,162 shares of the biopharmaceutical company’s stock valued at $8,518,000 after acquiring an additional 29,324 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Celldex Therapeutics by 40.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,111 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 4,093 shares in the last quarter. Arizona State Retirement System lifted its holdings in Celldex Therapeutics by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 16,231 shares of the biopharmaceutical company’s stock worth $601,000 after purchasing an additional 325 shares in the last quarter. Los Angeles Capital Management LLC boosted its stake in Celldex Therapeutics by 9.5% in the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 638 shares during the period. Finally, Quest Partners LLC grew its holdings in Celldex Therapeutics by 1,364.9% during the 2nd quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 6,879 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.